Table 4Relapse outcomes based on steroid use or hospitalization

Outcome measureFingolimod 0.5 mg once daily
N = 429
Fingolimod 1.25 mg once daily
N = 420
Interferon beta-1a
N = 431
Steroid use (%)11.213.118.3
Annualized relapse rate requiring steroids0.0840.1150.176
P value vs. interferon beta-1aP<0.001P<0.012--
Hospitalization (%)1.93.17.0
Annualized relapse rate requiring hospitalization0.0220.0390.077
P value vs. interferon beta-1aP=0.001P=0.049--

From: Results

Cover of Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod
Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original Report [Internet].
McDonagh M.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011 by Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.